Stay Updated with the Latest Ligand Pharmaceuticals Incorporated LGND News in Real Time
Find LGND news now at Meyka AI. Stay informed with the latest Ligand Pharmaceuticals Incorporated stocks updates, including price news, market analysis, and expert insights.
England Bans Deep-Fried School Meals From September 2027
England’s government bans deep-fried foods and cuts desserts in schools from September 2027 to fight obesity. New standards require more vegetables, wholegrains and lentils on menus.
US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge
US trade deficit reached $88.6 billion in July 2026, up 24% from June. AI-driven demand for semiconductors and computers pushed imports to record highs while exports fell 2.1%.
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…
Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model
Gaja Alternative IPO’s Grey Market Premium stood at ₹21 as of Thursday, August 20, 2026, 9:45 AM IST. That implies a listing price near ₹181, a 13% premium over the ₹160 upper band. The ₹550 crore issue from Gaja Capital’s asset management arm closes for subscription on August 21. Overall subscription remained modest at 0.30…
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.
AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit
AstraZeneca has halted a late-stage trial of its lung cancer drug Volrustomig, marking a fresh pipeline setback. The FTSE 100 company said the drug, combined with chemotherapy, was unlikely to improve survival rates. An Independent Data Monitoring Committee recommended stopping the Phase 3 trial after a planned review. This marks AstraZeneca’s second major trial halt…
2,500 Organizations Hit by LiteLLM Supply Chain Attack in March
LiteLLM supply chain attack in March 2026 exposed 2,500+ organizations and 434,000 CI/CD pipelines. Malicious code ran for 40 minutes, stealing AWS, GCP, and Azure credentials from major tech companies.
Technocraft Ventures IPO Subscription Hits 6.98x on Day 3 as NII Demand Leads
Technocraft Ventures IPO closed its subscription window Tuesday, August 11, 2026, at 6.98 times overall. Non-institutional investors drove the strongest demand, pushing this EPC infrastructure issue well past full subscription. The ₹251.88 crore mainboard IPO priced shares between ₹200 and ₹212. Strong grey market activity suggests investors expect a solid listing debut this week. Technocraft…
MV Electrosystems Debuts at 22% Premium on NSE, Lists at ₹520 Against IPO Price of ₹425
MV Electrosystems shares listed on the NSE on Thursday, August 6, 2026, at ₹520 per share. That marks a 22% premium over the IPO price of ₹425. The railway equipment maker’s mainboard debut drew strong investor interest throughout its three-day subscription window. Trading began at 10 a.m. on both NSE and BSE simultaneously. MV Electrosystems…